References
1. Blackford N, Jackson P. Mol Cell. 2017;66:801-817; 2. Ford JM, Kastan MB. In: Abeloff's Clinical Oncology. Elsevier. 2019:154-164; 3. Minten EV, Yu DS. Clin Oncol (R Coll Radiol). 2019;31:303-310; 4. Carrassa L, Damia G. Cancer Treat Rev. 2017;60:139-151; 5. Li Y, et al. Cell Rep. 2019;28:735-745; 6. Cremona CA, Behrens A. Oncogene. 2014;33:3351-3360; 7. Zenke FT, et al. Mol Cancer Ther. 2020;19:1091-1101; 8. Pospisilova M, et al. J Physiol Pharmacol. 2017;68:337-344; 9. Yap TA, et al. Clin Cancer Res. Published online February 26, 2024, doi:10.1158/1078-0432.CCR-23-2409; 10. Siu L, et al. Cancer Res . 2024;84 (Supp 7): CT063; 11. ClinicalTrials.gov. Accessed March 29, 2024, https://clinicaltrials.gov/ct2/show/NCT04170153; 12. ClinicalTrials.gov. Accessed March 29, 2024. https://clinicaltrials.gov/ct2/show/NCT05396833; 13. ClinicalTrials.gov. Accessed March 29, 2024. https://clinicaltrials.gov/study/NCT05882734; 14. Zimmermann A, et al. Mol Cancer Ther. 2022;21(6):859-870; 15. Zhang Q, et al. Cancer Res. 2019;79(15):3940-3951; 16. ClinicalTrials.gov. Accessed March 29, 2024. https://clinicaltrials.gov/ct2/show/NCT04882917; 17. ClinicalTrials.gov. Accessed May 31, 2024. https://clinicaltrials.gov/study/NCT06421935